Patient data ownership: who owns your health?

Abstract This article answers two questions from the perspective of United Kingdom law and policy: (i) is health information property? and (ii) should it be? We argue that special features of health information make it unsuitable for conferral of property rights without an extensive system of data-s...

Full description

Saved in:
Bibliographic Details
Published inJournal of law and the biosciences Vol. 8; no. 2; pp. K1 - lsab023
Main Authors Liddell, Kathleen, Simon, David A, Lucassen, Anneke
Format Journal Article
LanguageEnglish
Published Oxford University Press 01.07.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract This article answers two questions from the perspective of United Kingdom law and policy: (i) is health information property? and (ii) should it be? We argue that special features of health information make it unsuitable for conferral of property rights without an extensive system of data-specific rules, like those that govern intellectual property. Additionally, we argue that even if an extensive set of rules were developed, the advantages of a property framework to govern health information would be slight: propertization is unlikely to enhance patient self-determination, increase market efficiency, provide patients a foothold in the data economy, clarify legal uses of information, or encourage data-driven innovation. The better approach is to rely less, not more, on property. We recommend a regulatory model with four signature features: (i) substantial protection for personal health data similar to the GDPR with transparent limits on how, when, and by whom patient data can be accessed, used, and transmitted; (ii) input from relevant stakeholders; (iii) interoperability; and (iv) greater research into a health-data service, rather than goods, model.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Research Fellow, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School; Affiliated Fellow, Hanken School of Economics.
Professor of Clinical Genetics, Honorary Consultant in Clinical Genetics, Wessex Clinical Genetics Service, Clinical Ethics and Law Unit, Faculty of Medicine, University of Southampton.
Director, Centre for Law, Medicine and Life Sciences, University of Cambridge, Faculty of Law.
ISSN:2053-9711
2053-9711
DOI:10.1093/jlb/lsab023